

Bulletin #1097

January 30, 2023

NB Drug Plans Formulary Update

This update to the New Brunswick Drug Plans Formulary is effective January 30, 2023.

Included in this bulletin:

- Regular Benefit Additions
- Changes to Existing Special Authorization Benefits
- Drugs Reviewed and Not listed

If you have any questions, please contact our office at 1-800-332-3691.

Regular Benefit Additions

Generic name (Brand name)	Strength	DIN	MFR	Plans	Cost Base
Insulin glargine (Semglee)	100 unit/mL prefilled pen	02526441	BGP	ACDEFGV	MLP
Lidocaine (Xylocaine Ointment 5%)	5% topical ointment	00001961	APN	ACDEFGV	MLP
Tazarotene (Arazlo)	0.045% topical lotion	02517868	BSL	ACDEFGV	MLP

Special Authorization No Longer Required

Cabergoline (Dostinex and generic brand)	0.5 mg tablet	See NB Drug Plans Formulary or MAP List for Products		ACDEFGV	MAP
Linagliptin (Trajenta)	5 mg tablet	02370921	BOE	ACDEFGV	MLP
Sitagliptin (Januvia and generic brand)	25 mg tablet 50 mg tablet 100 mg tablet	See NB Drug Plans Formulary or MAP List for Products		ACDEFGV	MAP
Sitagliptin and Metformin (Janumet and generic brand)	50 mg / 500 mg tablet 50 mg / 850 mg tablet 50 mg / 1000 mg tablet	See NB Drug Plans Formulary or MAP List for Products		ACDEFGV	MAP
Sitagliptin and Metformin (Janumet XR and generic brand)	50 mg / 500 mg extended- release tablet 50 mg / 1000 mg extended- release tablet 100 mg / 1000 mg extended- release tablet	See NB Drug Plans Formulary or MAP List for Products		ACDEFGV	MAP

Temporary Benefit Addition

Due to the manufacturer shortage of rifampin (Rofact) 150 mg and 300 mg capsules, rifampin powder compounded for oral use has been added as a temporary regular benefit until commercial dosage forms become available. The PIN can be used to submit claims for any strength. Please note that claims for extemporaneous preparations will be reimbursed at the Actual Acquisition Cost (AAC) of the ingredients plus the applicable dispensing fee.

Product	PIN	Plans	Cost Base
Rifampin powder compounded for oral use	00904811	ACDEFGPVW	AAC

Changes to Existing Special Authorization Benefits

Generic name (Brand name)	Strength	DIN	MFR	Plans	Cost Base
New Dosage Form					
Dupilumab (Dupixent)	200 mg / 1.14 mL prefilled pen	02524252	SAV	(SA)	MLP

For the treatment of moderate to severe atopic dermatitis in patients 12 years of age and older who meet all of the following criteria:

- Refractory or have contraindications to an adequate trial of topical prescription therapies.
- Refractory, intolerant or have contraindications to an adequate trial of phototherapy (where available), methotrexate, and cyclosporine.
- Baseline Physician Global Assessment score of 3 or greater and Eczema Area and Severity Score of 7.1 or greater.

Renewal criteria

- Requests for renewal must provide proof of beneficial clinical effect defined as a 75% or greater improvement from baseline in the Eczema Area and Severity Index (EASI-75) score six months after treatment initiation.
- Proof of maintenance of EASI-75 response from baseline must be provided for subsequent authorizations.

Clinical Note:

- Not to be used in combination with phototherapy or immunosuppressant drugs (e.g., methotrexate, cyclosporine).

Claim Notes:

- Must be prescribed by a dermatologist.
- Approvals will be for a maximum of 600 mg at week 0, then 300 mg every two weeks thereafter.
- Initial approval period: 6 months.
- Renewal approval period: 1 year.

Drugs Reviewed and Not Listed

Requests for special authorization of the following products will not be considered.

Generic name (Brand name)	Strength	DIN	MFR	Indication
Dabrafenib (Tafinlar)	50 mg capsule	02409607	NVR	In combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer with a BRAF V600 mutation who have not received any prior anticancer therapy for metastatic disease.
	75 mg capsule	02409615		

Glycopyrronium (Cuvposa)	1 mg / 5 mL oral solution	02469332	MDX	To reduce chronic drooling in children aged 3-18 years with neurologic conditions.
Semaglutide (Rybelsus)	3 mg tablet	02497581	NNO	Type 2 diabetes mellitus.
	7 mg tablet	02497603		
	14 mg tablet	02497611		
Trametinib (Mekinist)	0.5 mg tablet	02409623	NVR	In combination with dabrafenib for the treatment of patients with metastatic non-small cell lung cancer with a BRAF V600 mutation who have not received any prior anticancer therapy for metastatic disease.
	2 mg tablet	02409658		